SLC5A12

Across TCGA pan-cancer cohorts, SLC5A12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC5A12 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SLC5A12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC5A12 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

BRCA, UCEC, and UVM are the cancer types where SLC5A12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.676	0.963	<.001	30	view →
UCEC	DFS	Median	II,III,IV	0.915	0.438	.034	8	view →
UVM	DFS	Median	All	0.180	0.744	.019	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →
LUSC	DFS	Median	All	1.000	0.752	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC5A12–BRCA (OS)

Open the BRCA breakdown →